FORA Capital’s Arcus Biosciences RCUS Stock Holding History

FORA Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,874	Closed	-$134K	–	754
2021 Q2	$134K	Buy	4,874 +2,865	+143%	+$81.8K	0.02%	525
2021 Q1	$56K	Sell	2,009 -2,529	-56%	-$88K	0.02%	525
2020 Q4	$118K	Buy	+4,538	New	+$110K	0.02%	629
2020 Q3	–	Sell	-5,408	Closed	-$134K	–	928
2020 Q2	$134K	Buy	+5,408	New	+$146K	0.05%	427

Other funds holding RCUS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

FORA Capital's RCUS Position: Q3 2021 in Review

FORA Capital sold out of Arcus Biosciences (RCUS) in Q3 2021, closing a stake of 4,874 shares — an estimated $134K sold.

FORA Capital first reported a position in RCUS in Q2 2020 and held it in 4 quarters. The position peaked at $134K in Q2 2021. 131 funds tracked by Wall St. Rank hold RCUS as of Q3 2021.

FORA Capital reported no remaining Arcus Biosciences position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 4,874 Arcus Biosciences shares in Q3 2021, an estimated $134K.
FORA Capital first reported a position in Arcus Biosciences in Q2 2020 and held it in 4 quarters.
FORA Capital's Arcus Biosciences position peaked at $134K in Q2 2021.
131 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.